Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 08:41:26 - browse：2

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： MD Anderson's Padmanee Sharma responds to research credit suit

explore

WSS

Opioid cravings were reduced by anti

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

First U.S. drug developed to treat liver disease MASH is approved

As AI in medicine takes off, can 'human in the loop' prevent harm?

WuXi out of biotech trade group, U.S. and China relations to blame

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

UCLA team creates talking throat patch for voice disorders

DIEP, the 'gold standard' of breast reconstruction, is under threat

UCLA team creates talking throat patch for voice disorders

Virginia high school admissions case could be legal follow

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

State Dept. review finds Biden bears some blame for Afghanistan failures

Why scientists need input from humanists on sensitive research

How to save PrEP access — and even expand it

In 'major milestone,' FDA approves first cell therapy for solid tumors

focus

Boston's new lab space is opening empty

Reporting on presidential health from Reagan to Trump and Biden

Abridge raises $150m as clinical notes automation market heats up

First U.S. drug developed to treat liver disease MASH is approved

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

WATCH: Why do our ears pop?

leisure time

hotspot

explore

hotspot